Tremfya

GPTKB entity

Statements (54)
Predicate Object
gptkbp:instance_of gptkb:pharmaceuticals
gptkbp:administered_by subcutaneous injection
gptkbp:approves gptkb:European_Union
gptkb:United_States
gptkbp:class immunomodulator
gptkbp:clinical_trial gptkb:DISCOVER-1
gptkb:DISCOVER-2
Phase 3
active psoriatic arthritis
moderate to severe plaque psoriasis
VOYAGE 1
VOYAGE 2
gptkbp:contraindication hypersensitivity to guselkumab
gptkbp:dosage_form solution for injection
gptkbp:effective_date July 2017
gptkbp:financial_support available for eligible patients
gptkbp:formulation single-dose prefilled syringe
gptkbp:frequency once every 8 weeks after initial doses
https://www.w3.org/2000/01/rdf-schema#label Tremfya
gptkbp:ingredients gptkb:guselkumab
gptkbp:invention 2027
gptkbp:is_monitored_by allergic reactions
infections
liver function tests
gptkbp:manufacturer gptkb:Janssen_Pharmaceuticals
gptkbp:marketed_as gptkb:brand
gptkbp:mechanism_of_action IL-23 inhibitor
gptkbp:patient_population adults
children over 6 years old
gptkbp:pharmacokinetics reduces IL-23 levels
steady-state concentration achieved by week 16
gptkbp:price varies by region
gptkbp:provides_guidance_on recommended for certain patients with psoriasis
recommended for certain patients with psoriatic arthritis
gptkbp:regulatory_compliance approved by FDA
approved by EMA
gptkbp:requires available online
gptkbp:research ongoing for other indications
gptkbp:route_of_administration subcutaneous
gptkbp:safety_measures risk of serious infections
risk of allergic reactions
gptkbp:sales available in multiple countries
gptkbp:side_effect fatigue
headache
thrombosis
injection site reactions
increased risk of malignancies
gptkbp:storage refrigerated
gptkbp:type_of_care important for treatment efficacy
gptkbp:type_of_insurance may vary by plan
gptkbp:used_for treatment of psoriatic arthritis
treatment of plaque psoriasis
gptkbp:bfsParent gptkb:Eli_Lilly
gptkbp:bfsLayer 4